We're excited to share that abstracts on updated data from the LOTIS-7 Phase 1b trial evaluating our CD19-targeted #antibodydrugconjugate in combination with the bispecific antibody glofitamab to treat relapsed/refractory (r/r) diffuse large B-cell lymphoma (#DLBCL) have been accepted for presentation at #EHA2025 and #18ICML. Full presentation details here: https://xmrrwallet.com/cmx.plnkd.in/e9mEbv_h
Oncology Specialist: Hematology|CAR T|Start Up|Rare Disease| Patient Focused
2moBest of luck here Brad and all. You have all worked so hard!! I look forward to hearing more!